- This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024.
NE BUSINESS BUREAU
MUMBAI, AUG 26
Following the Anvisa approval of an oral dose manufacturing unit, Eris Lifesciences Limited, a leading Indian branded formulations company, on Tuesday announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil’s national health regulatory agency. This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024.
The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, and the company expects to receive approval for the second facility soon. Both facilities are already EU-GMP and PIC/s approved and supply a range of products to several Latin American markets, including Mexico, Chile, Argentina and Peru. A company spokesperson said that the Anvisa approval would enable the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market.
Commenting on the development, Amit Bakshi, CMD of Eris said, ‘We take this approval as yet another endorsement of our operating and quality standards in life-saving dosage forms like injectables. This approval takes us a step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. We made major investments to initiate this transformation last year and we are glad to note that we have made significant progress in creating value from these investments with many more exciting developments expected in the quarters to come.”
